SEINE BIO · SCIENCE LIBRARY
Mecasermin / IGF-1
Mecasermin is recombinant human IGF-1 used in specified pediatric growth disorders.
Approved product · specific indicationsA closer look at the research, the uncertainties and the questions worth asking.
THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026
Inside the science of Mecasermin / IGF-1.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is an option only where the particular substance, product, and prescribing pathway are lawful; a pharmacy cannot make every research compound available for patient use. Approved finished medicines may also be obtained from licensed non-compounding pharmacies.
Overview
Mecasermin is recombinant human IGF-1 supplied as the approved medicine Increlex for defined pediatric growth-failure conditions. It is different from experimental LR3 and DES analogs. An approved disease-specific medicine should not be presented as a general adult anti-aging or muscle-building product merely because its mechanism involves growth.
Community Use
IGF-1 terminology appears in performance-oriented discussion, but the approved medicine and experimental analogs need separate treatment. No exact mecasermin protocol from PeptideDosages.com and Peptidepedia was cited here, so none is attributed to them. The current finished-product label is the appropriate reference for the approved clinical context.
Doses, Durations & Cycles
Published dosing regimens. Product-label and study regimens for education, not instructions for self-treatment. Product, indication and route matter.
| Route / formulation | Dose / reported phases | Frequency | Duration / break | Notes and source |
|---|---|---|---|---|
| Subcutaneous | Initial 0.04–0.08 mg/kg per dose; after at least one week, increments of 0.04 mg/kg per dose; label maximum 0.12 mg/kg per dose | Twice daily | Pediatric severe primary IGF-1 deficiency; no bodybuilding cycle Break: No routine cycling interval | FDA prescribing information INCRELEX |
Important context: Prescription use requires food and monitoring because severe hypoglycemia can occur. This is not an adult performance regimen.
Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.
The Increlex label sets a pediatric, weight-based, clinician-managed regimen with important monitoring requirements. It is not an adult performance schedule, and its values must not be applied to LR3 or DES. The chart describes pediatric label information, not an adult enhancement cycle.
Research Findings
A 2007 long-term study treated 76 children with severe IGF-1 deficiency due to growth-hormone insensitivity, predominantly under an open-label design. Growth velocity improved, especially in the first year. The selected pediatric population and study design matter: these results cannot establish benefit for adults seeking appearance or performance changes.
U.S. Approval & Access
Increlex is an approved prescription product for specific pediatric growth-failure circumstances. Approval does not transfer to experimental analogs or authorize every use of IGF-1. A clinical decision must match the patient and product; this educational page is not an adult IGF-1 offer or a promise of prescribing.
What It Does in the Body
IGF-1 participates in growth and metabolic signaling. The label estimates a terminal half-life of about 5.8 hours in one pediatric deficiency context. That is not a general adult exposure estimate or an onset of visible benefit. Growth outcomes are assessed longitudinally; a reliable peak-benefit timeline for adult enhancement is not established.
Benefits & Reported Experiences
The original study concerned height growth in a rare diagnosed condition, not muscle gain or general wellness. Improved growth velocity also does not guarantee a particular final height. Any clinical result should be interpreted alongside diagnosis, age, skeletal maturity, duration of treatment, and the limitations of the study.
Side Effects & Risks
Important labeled risks include severe hypoglycemia, intracranial hypertension, lymphoid tissue enlargement, and neoplasia concerns. This is not a complete safety list. A caregiver and clinical team need a monitoring and response plan; the medicine’s approval does not make it suitable for every child or for healthy adults.
Delivery Options
Increlex is a finished solution supplied for its authorized route. It is not a research powder or an interchangeable IGF analog. The prescribed product’s instructions and clinical training govern use; this page intentionally does not reproduce injection technique, dose calculations, or preparation instructions.
Product Quality & Storage
The Increlex label requires refrigeration at 2–8°C, protection from direct light, and avoidance of freezing. After initial vial entry, the labeled refrigerated use period is 30 days. These instructions apply to Increlex, not other IGF products; always follow the actual dispensed product’s current labeling.
Combinations & Interactions
Combining mecasermin with other hormone-active products is not established by the pediatric growth study. Other treatments must be reviewed by the specialist, and experimental analogs should not be treated as substitutes or additions with inherited evidence. No performance stack, cycle, or consumer combination timing is provided.
Talking With Your Provider
A suspected pediatric growth disorder needs specialist evaluation of the actual cause, not selection of a peptide from an online list. Adults with fatigue or body-composition concerns need assessment appropriate to those symptoms. A consultation can clarify evidence and established options without promising IGF-1 access or enhancement.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is an option only where the particular substance, product, and prescribing pathway are lawful; a pharmacy cannot make every research compound available for patient use. Approved finished medicines may also be obtained from licensed non-compounding pharmacies.
Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.
Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.
Questions worth bringing to your appointment.
- Are there alternatives that address my goal?
- If treatment is appropriate, what monitoring and follow-up would I need?
- Could my health history or current medicines change the risks?
Saved discussion topics 0
Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.
Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.
Explore your next step with SEINE BIO.
Bring your questions to a wellness consultation. Inclusion in this library does not indicate prescribing or product availability. A consultation does not guarantee a prescription.
Explore consultations Back to Growth-hormone signalingEducational information · U.S. context · October 7, 2026. No ordering, personalized dosing or injection instructions.
Bring your saved topics to your care team.
Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.
Choose saved topics for review →